Abstract Library

#4394 Application of somatostatin receptor PET/CT in assisting preoperative lymph node evaluation and surgical decision-making for duodenal and pancreatic neuroendocrine neoplasms

Introduction: Preoperative precise staging of lymph nodes is crucial for determining surgical approach and extent for duodenal and pancreatic neuroendocrine neoplasms (DP-NENs), especially for small (≤2cm) DP-NENs.

Conference:

Presenting Author:

Authors: Xianze W, Bohui Y, Wenjia Z, Wensheng L, Meixi L,

Keywords: 68Ga-SSTR PET/CT, neuroendocrine neoplasm, lymph node metastasis, surgical decision-making,

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#4310 [18F]AlF-NOTA-octreotide as tracer for somatostatin receptor PET/CT: Retrospective analysis of the clinical use in 288 neuroendocrine tumour patients

Introduction: [18F]AlF-NOTA-octreotide has emerged as a reliable tracer for somatostatin receptor (SSTR) PET/CT in patients with neuroendocrine neoplasms (NENs). Although effective and logistically advantageous, there remains limited data on its routine clinical application, particularly for specific NEN subtypes (e.g. NET G3).

Conference:

Presenting Author: Leupe H

Authors: Leupe H, Dekervel J, Cleeren F, Goffin K, Dooms C,

Keywords: [18F]AlF-NOTA-octreotide, routine clinical use, neuroendocrine tumour, somatostatin receptor, PET/CT imaging,

#3659 The characteristics of somatostatin receptor PET/CT in bone metastases of neuroendocrine tumors

Introduction: Bone metastasis is a poor prognostic predictor of neuroendocrine neoplasms.

Conference:

Presenting Author: Xu J

Authors: Xu J, Xu X, Song S, Chen J,

Keywords: Bone metastasis of neuroendocrine neoplasms, 68Ga-DOTATATE, 68Ga-DOTANOC, PET/CT,

#1529 Somatostatin Receptor PET/CT with Radiolabelled Antagonist Is Twice as Effective as the Agonist for Detecting Liver Metastases: Results of a Phase 1/2 Study Comparing 68Ga-OPS202 with 68Ga-DOTATOC PET/CT in Gastroenteropancreatic NET Patients

Introduction: 68Ga-DOTATOC PET/CT is a reference method for imaging somatostatin receptor (sstr) expressing neuroendocrine tumors (NET). Presence and extent of liver metastases impact on patient management and prognosis.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Nicolas G

Authors: Nicolas G, Schreiter N, Kaul F, Uiters J, Mena R,

Keywords: Radiolabelled somatostatin antagonist, PET, GEP-NET,